Abstract
The effect of insulin lispro Mixture-25 and Mixture-50 on the quality of life (QOL) of Type 1 and Type 2 diabetes patients was assessed by means of the QOL questionnaire “Insulin Therapy Related QOL (ITR-QOL)”. Insulin lispro is a rapid-acting insulin analogue and administered to patients immediately before meals. In this open-label trial patients received lispro Mixture-25 or lispro Mixture-50 and the QOL assessment was performed turce : at the start of therapy and after 12 weeks of therapy.
The subjects of the analysis in this study consisted of 215 of the 238 patients enrolled. The average score on the ITR-QOL was significantly higher at the endpoint (99.2 points) than at baseline (94.2 points), demonstrating improvement of the patients' QOL. The largest incremeases in scores (+0.4 to +1.0 points) on the ITR-QOL were observed in the items related to meal in the domain of “Perception Score”. Compliance with treatment and adherence to the physician's instructions regarding treatment were significantly better. The improvements were similar to those observed in the clinical study on lispro multiple-injection therapy. Thus, the lispro mixture medications improve patients' QOL.
